ANXA3 levels correlated with worse overall survival in sorafenib-treated HCC patients, and combination of anti-ANXA3 monoclonal antibody and sorafenib or regorafenib inhibited HCC tumor growth in vivo with significant increase in survival [108]. The gene discussed is ANXA3; the disease is hepatocellular carcinoma.